Shilpa Medicare Ltd. engages in the manufacturing of pharmaceutical products and wind power generation. The company is headquartered in Raichur, Karnataka and currently employs 1,033 full-time employees.  The firm is engaged in research and development, manufacturing and sale of oncology drugs and formulations. Its products consist of oncology and non-oncology active pharmaceutical ingredients (APIs), oncology formulations, biosimilars, ophthalmic, oral dissolving films, biochemical diagnostics, organic intermediates, pilot and production scales and transdermal patches. The company supplies oncology APIs and intermediates. Its oncology/non-oncology APIs include Capecitabine, Gemcitabine Hydrochloride, Axitinib, Erlotinib HCL, and Irinotecan HCL Trihydrate for various regulated markets, including United States of America, Europe, Japan, South Korea, Russia, Mexico, Brazil, and other emerging markets. Its non-oncology APIs products include Ambroxol (Mucolytic agent) in Europe and Tranexmic Acid and Ursodeoxycholic acid in India. The company is also engaged in manufacturing and sale of Lenvatinib Capsules under the brand name Lenshil.

Shilpa Dividends

SHILPAMED.NS dividend metrics

Dividend per share

SHILPAMED.NS dividend history